Johnson & Johnson announced on Tuesday a new collaboration between Janssen Pharmaceutica NV and the Stichting International Dispensary Association to provide access to an anti-tuberculosis medicine.
"Multidrug-resistant tuberculosis is a complex public health problem," Janssen Worldwide Chairman and Johnson & Johnson Chief Scientific Officer Paul Stoffels said. "We feel we have a responsibility to work together with others in the TB community in order to tackle this challenge."
The collaboration will provide access to the medication for more than 130 low- and middle-income countries outside the United States.
"We are committed to enhancing access to medicines through public-private partnerships, differentiated pricing and responsible use and distribution of medicines," Janssen Vice President of Global market Access Adrian Thomas said. "We believe that the collaboration with the Stop TB Partnership's Global Drug Facility is a good example of how we can contribute to the collective global access response for public health medicines."
Janssen Global Public Health works to provide access to medication and treatment developed by the Janssen Pharmaceutical Companies of Johnson & Johnson. The company expands access to medication through collaboration and supporting public health solutions.
Janssen GPH focuses on multidrug resistant tuberculosis, HIV, elephantiasis, intestinal worms and river blindness. The company is working to integrate mobile technology into health systems to improve outcomes.